![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
14MB |
![[thumbnail of Supplementary Material]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Material)
11MB |
| Item Type: | Article |
|---|---|
| Title: | TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets |
| Creators Name: | Decaesteker, B., Denecker, G., Van Neste, C., Dolman, E.M., Van Loocke, W., Gartlgruber, M., Nunes, C., De Vloed, F., Depuydt, P., Verboom, K., Rombaut, D., Loontiens, S., De Wyn, J., Kholosy, W.M., Koopmans, B., Essing, A.H.W., Herrmann, C., Dreidax, D., Durinck, K., Deforce, D., van Nieuwerburgh, F., Henssen, A., Versteeg, R., Boeva, V., Schleiermacher, G., van Nes, J., Mestdagh, P., Vanhauwaert, S., Schulte, J.H., Westermann, F., Molenaar, J.J., De Preter, K. and Speleman, F. |
| Abstract: | Chromosome 17q gains are almost invariably present in high-risk neuroblastoma cases. Here, we perform an integrative epigenomics search for dosage-sensitive transcription factors on 17q marked by H3K27ac defined super-enhancers and identify TBX2 as top candidate gene. We show that TBX2 is a constituent of the recently established core regulatory circuitry in neuroblastoma with features of a cell identity transcription factor, driving proliferation through activation of p21-DREAM repressed FOXM1 target genes. Combined MYCN/TBX2 knockdown enforces cell growth arrest suggesting that TBX2 enhances MYCN sustained activation of FOXM1 targets. Targeting transcriptional addiction by combined CDK7 and BET bromodomain inhibition shows synergistic effects on cell viability with strong repressive effects on CRC gene expression and p53 pathway response as well as several genes implicated in transcriptional regulation. In conclusion, we provide insight into the role of the TBX2 CRC gene in transcriptional dependency of neuroblastoma cells warranting clinical trials using BET and CDK7 inhibitors. |
| Keywords: | Antineoplastic Agents, Azepines, Brain Neoplasms, Cell Survival, Cyclin-Dependent Kinases, DNA Copy Number Variations, Genetic Epigenesis, Forkhead Box Protein M1, HEK293 Cells, Histones, Kv Channel-Interacting Proteins, N-Myc Proto-Oncogene Protein, Neoplastic Gene Expression Regulation, Neuroblastoma, Organoids, Panobinostat, Phenylenediamines, Pyrimidines, Repressor Proteins, Signal Transduction, T-Box Domain Proteins, Triazoles, Tumor Cell Line, Tumor Suppressor Protein p53 |
| Source: | Nature Communications |
| ISSN: | 2041-1723 |
| Publisher: | Nature Publishing Group |
| Volume: | 9 |
| Number: | 1 |
| Page Range: | 4866 |
| Date: | 19 November 2018 |
| Official Publication: | https://doi.org/10.1038/s41467-018-06699-9 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
